Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Long-term complications with prostate implants: iodine-125 vs. palladium-103.

R E Peschel1, Z Chen, K Roberts

  • 1Department of Therapeutic Radiology, Yale University School of Medicine, New Haven, Connecticut 06520-8040, USA. richard.peschel@yale.edu

Radiation Oncology Investigations
|December 2, 1999
PubMed
Summary

Palladium-103 (Pd-103) brachytherapy for prostate cancer shows lower complication rates than Iodine-125 (I-125). Pd-103 offers a better safety profile and potentially higher tumor cell kill, even with adjusted doses.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Nutrition Support in Critically Ill Adults in Intensive Care Units: An Evidence Analysis Center Scoping Review of Current Systematic Reviews and Guidelines.

Journal of the Academy of Nutrition and Dietetics·2026
Same author

Shaping a better future for children living with rare diseases: The pivotal role of paediatric nurses.

Journal of pediatric nursing·2025
Same author

Resolution in Two-Photon Imaging: A Local Manifestation of Entanglement.

ACS photonics·2025
Same author

CT and MRI activity in England: insights from the diagnostic imaging dataset.

Clinical radiology·2025
Same author

A cognitive help or hindrance? A systematic review of cognitive behavioural therapy to treat anxiety in young people with autism spectrum disorder.

Clinical child psychology and psychiatry·2025
Same author

Optimising detector readout settings for the detection of spatial correlations between SPDC photon-pairs.

Scientific reports·2025

Area of Science:

  • Oncology
  • Medical Physics
  • Radiotherapy

Background:

  • Prostate cancer brachytherapy commonly uses Iodine-125 (I-125) and Palladium-103 (Pd-103) isotopes.
  • The linear quadratic model predicts differences in biologically effective dose (BED) and complication rates between I-125 and Pd-103.
  • Current prescribed minimum tumor doses (MTD) for I-125 (160 Gy) and Pd-103 (115 Gy) are used in brachytherapy.

Purpose of the Study:

  • To compare the normal tissue complication rates between Pd-103 and I-125 prostate brachytherapy.
  • To evaluate the radiobiological effectiveness of Pd-103 versus I-125 in terms of tumor cell kill.
  • To explore future research directions for prostate brachytherapy implants.

Main Methods:

  • Utilized the linear quadratic model to predict BED for Pd-103 and I-125.

Related Experiment Videos

  • Reviewed clinical data from 123 early-stage prostate cancer patients treated at Yale University (82 with I-125, 41 with Pd-103).
  • Conducted a literature review of 992 patients treated with I-125 versus 540 patients treated with Pd-103.

    • Main Results:

    • Pd-103 brachytherapy demonstrated significantly lower overall complication rates (0%) compared to I-125 (13%).
    • Grade III-IV complication rates were 0% for Pd-103 versus 6% for I-125.
    • The 3-year complication-free survival was 100% for Pd-103 compared to 82% for I-125 (P<0.01).
    • Literature review consistently showed higher complication rates with I-125 than Pd-103.
    • Radiobiological modeling predicts greater log10 cell kill for Pd-103, even with equivalent normal tissue BED.

    Conclusions:

    • Pd-103 prostate brachytherapy is associated with a superior safety profile and lower complication rates compared to I-125.
    • Pd-103 may offer enhanced tumoricidal effect, supporting its use in prostate cancer treatment.
    • Further research should investigate optimizing Pd-103 dosing for maximal efficacy and minimal toxicity.